SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

coramitug

PRTA·PROTHENA CORP PUBLIC LTD CO
MIXED
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
If Phase 3 succeeds, potential FDA submission would likely be in 2029-2030, with commercialization following 1-2 years later.
Why 4/10
The next hard catalyst for coramitug is the Phase 3 CLEOPATTRA trial primary completion, expected in 2029 (more than 12 months away). With no near-term binary catalyst, the impact score is set to the default of 4.
Actionable Insight MIXED

Coramitug has no near-term binary catalyst: the Phase 3 CLEOPATTRA trial's primary completion is expected in 2029. Watch for any interim analysis announcements from Novo Nordisk, which could move the stock if released early. The next major Prothena catalyst is the moponetug (PRX005) Phase 2 Alzheimer's data readout expected in 1H 2027, not coramitug.

Price Chart

Loading chart...

Executive Summary

Coramitug (formerly PRX004) is a potential first-in-class amyloid-depleter antibody being developed by Novo Nordisk for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a progressive and fatal heart condition. Prothena (NASDAQ: PRTA) originally discovered the drug and licensed worldwide rights to Novo Nordisk in 2021, earning $150 million in milestone payments to date from a potential $1.2 billion total package. Phase 2 data showed statistically significant biomarker improvements but were described as mixed, and the Phase 3 CLEOPATTRA trial (~1,280 patients) is now enrolling with primary completion expected in 2029. The drug faces entrenched competition from Pfizer's tafamidis and Alnylam's recently approved vutrisiran. For Prothena investors, coramitug is a partnered, long-duration pipeline asset with no near-term catalyst.

How It Works

Coramitug is a monoclonal antibody (a lab-made protein that targets a specific substance in the body) designed to directly clear away amyloid deposits. In ATTR amyloidosis with cardiomyopathy, misfolded transthyretin proteins clump together as amyloid fibrils that build up in the heart muscle, stiffening it and leading to heart failure. Unlike existing drugs that only prevent new amyloid from forming (stabilizers like tafamidis) or reduce production of the TTR protein (gene silencers like vutrisiran), coramitug aims to actively remove existing amyloid deposits from the heart tissue.

Trial Status

The Phase 3 CLEOPATTRA trial is actively recruiting approximately 1,280 participants with ATTR-CM. The trial achieved a prespecified enrollment milestone in early 2026, triggering a $50 million payment from Novo Nordisk. Primary completion is expected in 2029. The FDA granted Fast Track designation in April 2026.

The Two-Sided Case

▲ Bull Case5
Coramitug is a potential first-in-class amyloid depleter antibody, a differentiated mechanism that directly removes amyloid deposits rather than just stabilizing TTR protein like existing therapies.
Phase 2 data showed statistically significant NT-proBNP reduction and improved echocardiographic parameters at the 60 mg/kg dose, with results published in Circulation (AHA's official journal).
FDA granted Fast Track designation in April 2026, which can accelerate development and review.
Novo Nordisk is a deep-pocketed partner that has already paid $150M of $1.2B in eligible milestones, validating the program's potential and funding Prothena's operations.
Prothena's 10% owner William Scully has been aggressively buying shares on the open market, acquiring over $8M worth between September and October 2026 at prices around $8-9 per share.
▼ Bear Case5
Phase 2 data was described as 'mixed' by FierceBiotech, with questions about efficacy signal strength that led Novo Nordisk to advance to Phase 3 despite inconclusive results.
The ATTR-CM competitive landscape is intensifying: Pfizer's tafamidis (Vyndamax) is the established standard of care, Alnylam's vutrisiran (Amvuttra) was recently approved for ATTR-CM, and generics are emerging.
Phase 3 CLEOPATTRA trial won't read out until 2029, meaning coramitug contributes no near-term revenue or catalyst for Prothena shareholders.
Prothena has a history of Phase 3 failures: birtamimab failed the AFFIRM-AL trial in AL amyloidosis in May 2025, and PRX019 was terminated by Bristol Myers Squibb in October 2026.
As a partnered program, Prothena receives only milestones and royalties (up to $1.2B total), not the full commercial upside; Novo Nordisk controls development and commercialization decisions.

Upcoming Catalysts

  • Phase 3 CLEOPATTRA trial primary completion (expected 2029) - no near-term binary catalyst
  • Any potential interim analysis from Novo Nordisk (unconfirmed and not scheduled)
  • Additional milestone payments from Novo Nordisk upon achieving development milestones

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PROTHENA CORP PUBLIC LTD CO 8-K PRTA ·Originating report

Sources · 8

Hover a chip for the title
1 businesswire.com2 empr.com3 fiercebiotech.com4 sec.gov5 msn.com6 msn.com7 msn.com8 benzinga.com